

#3



Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DKT. NO. BAYER 9-C1	SERIAL NO. 09/472,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT DUMAS et al. William J. Scott	
		FILING DATE December 27, 1998	GROUP 1624 NOT YET ASSIGNED

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
VR	AA	3,823,161	07/09/74	Lesser	260 332.2	
VR	AB	5,130,331	07/14/92	Pascual	514 447	
VR	AC	4,808,588	02/28/89	King	514 212	
VR	AD	3,424,760	01/28/69	Helsley et al.	260 326.3	
VR	AE	3,424,761	01/28/69	Helsley et al.	260 326.3	
VR	AF	3,424,762	01/28/69	Helsley et al.	260 326.3	
VR	AG	4,071,524	01/31/78	Banitt	260 293.77	
VR	AH	4,111,683	09/05/78	Singer	71 104	
VR	AI	4,437,878	03/20/78	Acker et al.	71 90	
VR	AJ	4,643,849	02/17/87	Hirai et al.	540 955	
VR	AK	5,773,459	06/30/98	Tang et al.	514 585	
VR	AL	5,508,288	04/16/96	Forbes et al.	514 310	
VR	AM	4,062,861	12/13/77	Yukinaga et al.	260 307H	
VR	AN	4,111,680	09/05/78	Yukinaga et al.	71 104	
VR	AO	4,116,671	09/26/78	Yukinaga et al.	71 88	
VR	AP	4,212,981	07/15/80	Yukinaga et al.	548 246	
VR	AQ	5,162,360	11/10/92	Creswell et al.	514 371	
VR	AR	4,514,571	04/30/85	Nakai et al.	546 306	
VR	AS	3,754,887	08/28/73	Brantley	71 74	
VR	AT	3,646,059	02/29/72	Brantley	260 310	
VR	AU	5,696,138	12/9/97	Olesen et al.	514 349	
VR	AV	5,780,483	7/14/98	Widdowson et al.	514 311	
VR	AW	4,405,644	9/20/83	Kabbe et al.	424 322	
VR	AX	4,473,579	9/25/84	Devries et al.	424 282	
VR	AY	4,526,997	7/2/85	O'Doherty et al.	560 21	
VR	AZ	4,468,380	8/28/84	O'Doherty et al.	424 114	
VR	BA	4,623,662	11/18/86	De Vries	514 596	
VR	BB	4,985,449	1/15/91	Haga et al.	514 349	
VR	BC	5,312,820	5/17/94	Ashton et al.	514 227.5	
VR	BD	4,410,697	10/18/83	Török et al.	544 165	
VR	BE	4,001,256	1/4/97	Callahan et al.	260 295E	
VR	BF	5,399,566	3/21/95	Katano et al.	514 340	
VR	BG	5,500,424	3/19/96	Nagamine et al.	514 235.5	
VR	BH	5,597,719	1/28/97	Freed et al.	435 194	

Duyak Key

2/9/01

					Class	Sub	
VR	BI	4,183,854	1/80	Crossley	548	195	
VR	BJ	3,828,001	8/74	Broad et al.	260	232.2	
VR	BK	4,740,520	4/88	Hallenbach et al.	514	447	
VR	BL	5,319,099	6/7/94	Kamata et al.	548	538	
VR	BM	5,059,614	10/22/91	Lepage et al.	514	378	
VR	BN	3,743,498	07/03/73	Brantley	71	88	
VR	BO	3,547,940	12/15/70	Brantley	260	307	
VR	BP	5,432,468	7/11/95	Moriyama et al.			
VR	BQ	1,742,156	2/31	Fitzky			
VR	BR	2,046,375	07/36	Goldstein et al.	260	125	
VR	BS	2,093,265	9/36	Coffby et al.	260	125	
VR	BT	2,288,422	6/42	Rohm	260	506	
VR	BU	2,683,082	7/54	Hill et al.	44	71	
VR	BV	2,745,874	5/56	Schetty et al.	260	553	
VR	BW	2,781,330	2/57	Downey	260	45.9	
VR	BX	2,867,659	1/59	Model et al.	260	552	
VR	BY	2,877,268	3/59	Applegate et al.	260	553	
VR	BZ	2,960,488	11/60	Tamblyn et al.	260	45.9	
VR	CA	3,689,550	9/72	Schellenbaum et al.	260	553	
VR	CB	3,860,645	1/95	Nikawitz	260	553	
VR	CC	5,423,905	6/95	Fringeli	106	18.32	
VR	CD	2,973,386	2/61	Weldon	260	553	
VR	CE	3,230,141	1/66	Frick et al.	167	38.6	
VR	CF	4,863,924	9/89	Haga et al.	514	247	
VR	CG	4,511,571	4/85	Böger et al.	514	351	
VR	CH	4,173,638	11/79	Nishiyama et al.	424	263	
VR	CI	4,173,637	11/79	Nishiyama et al.	424	263	
VR	CJ	4,820,871	4/89	Kissener et al.	568	55	
VR	CK	4,983,605	1/91	Kondo et al.	514	247	
VR	CL	5,098,907	3/92	Kondo et al.	514	274	
VR	CM	5,036,072	7/91	Nakajama et al.	514	274	
VR	CN	5,470,882	11/95	Dixon et al.	514	596	
VR	CO	5,429,918	7/95	Seto et al.	430	551	
VR	CP	3,151,023	9/64	Martin	167	30	
VR	CQ	3,200,035	8/65	Martin et al.	167	38.6	
VR	CR	5,807,891	9/15/98	Bold et al.	514	487	
VR	CS	4,009,847	3/1/77	Aldrich et al.	424	275	


FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
VR	CT EP 335156	03/11/89	European				X
VR	CU EP 459887	05/28/91	European				X
VR	CV EP 371876	11/28/89	European				X

* not relevant.

Duyak Ray B

2/9/01



VR	CW	93/24458	12/9/93	WO WIPO			X	
VR	CX	2,146,707	10/12/95	Canada			X	
VR	CY	96/40673	12/19/96	WO WIPO			X	
VR	CZ	94/14801	07/07/94	WO WIPO			X	
VR	DA	94/25012	11/10/94	WO WIPO			X	
VR	DB	1,590,870	06/10/81	England			X	
VR	DC	93/18028	09/16/93	WO WIPO			X	
VR	DD	94/18170	08/18/94	WO WIPO			X	
VR	DE	DE 3305866 A1	02/19/83	Germany				X
VR	DF	95/02591	01/26/95	WO WIPO			X	
VR	DG	95/13067	05/18/95	WO WIPO			X	
VR	DH	95/07922	03/23/95	WO WIPO			X	
VR	DI	95/31451	11/23/95	WO WIPO			X	
VR	DJ	A1 96/40675	12/19/96	WO WIPO			X	
VR	DK	JP 53 086033	7/29/78	Japan				
VR	DL	JP 51 063170	6/1/76	Japan				
VR	DM	97/49400	12/31/97	WO WIPO				
VR	DN	97/49399	12/31/97	WO WIPO				
VR	DO	96/40673	12/19/96	WO WIPO				
VR	DP	99/00357	1/7/99	WO WIPO				
VR	DQ	97/45400	12/4/97	WO WIPO				
VR	DR	96/02112	3/8/90	WO WIPO				
VR	DS	99/00370	1/7/99	WO WIPO				
VR	DT	97/29743	8/21/97	WO WIPO				
VR	DU	98/22432	5/28/98	WO WIPO				
VR	DV	96/25157 A1	8/22/96	WO WIPO				
VR	DW	97/40028 A1	10/30/97	WO WIPO				
VR	DX	0 771 333	3/57	Great Britain				
VR	DY	0 921 682	3/63	Great Britain				
VR	DZ	0 253 997	2/88	East Germany				
VR	EA	0 405 233	1/91	Europe				
VR	EB	1 457 172	9/66	France				
VR	EC	0 487 014	12/29	Germany				
VR	ED	0 511 468	10/30	Germany				
VR	EE	0 523 437	5/31	Germany				
VR	EF	44 2569	2/69	Japan				
VR	EG	55 98152	7/80	Japan				
VR	EH	94 22807	10/94	WIPO				
VR	EI	3 532 47	3/91	Japan				
VR	EJ	0 828 231	10/56	Great Britain				
VR	EK	95/33458	12/95	WIPO				
VR	EL	50-149668	11/75	Japan				

Amraka Ray

2/9/01

✓	EM	55-162772	12/80	Japan				
✓	EN	50-76072	6/75	Japan				
✓	EO	51-80862	7/76	Japan				
✓	EP	50-77375	9/80	Japan				
✓	EQ	55-124763	9/80	Japan				
✓	ER	0 502 504	9/92	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	ES	Dumas, J., "CAS-Substructure," May 6, 1997, pages 1-29.
✓	ET	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
✓	EU	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
✓	EV	"Beilstein number" Collection, 28 pages.
✓	EW	"Beilstein Collection," 4 pages.
✓	EX	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
✓	EY	Substructure Search, pages 1-30.
✓	EZ	Derwent World Patents Index Search, pages 20-26.
✓	FA	Abstract of EP 116,932, 08/84.
✓	FB	Abstract of EP 676,395, 10/1995.
✓	FC	Abstract of EP 202,538, 11/1986.
✓	FD	Abstract of EP 16,371, 10/1980.
✓	FE	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway," TIBS 19; July 1994; pp. 279-282.
✓	FF	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95. <i>J. Med. Chem., 39(22)</i>
✓	FG	Audia, James E., et al., "Potent, Selective Tetrahydro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80. <i>J. Med. Chem., 39(14)</i>
✓	FH	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57. <i>J. Med. Chem., 38(6)</i>
✓	FI	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. A Generalised Monocyclic Rearrangement," 1967, 2005-07. <i>J. Chem. Soc. (C)</i>
✓	FJ	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
✓	FK	G. Daum, et al., "The ins and outs of Raf Kinases," TIBS 19, November 1994, pages 474-80.
✓	FL	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
✓	FM	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
✓	FN	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
✓	FO	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
✓	FP	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
✓	FQ	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
✓	FR	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
✓	FS	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
✓	FT	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.

Dipak Ray B

2/9/01

KUTUNDZIC ET AL.,

<i>VR</i>	FU	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.
<i>VR</i>	FV	Tarzia, G. et al. "Whythesis and antiinflammatory properties of some pyrrol(1H,3H)[3,4] pyrimidin-2-onesandpyrrolo(1H,3H)[3,4-d] pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558; page 594.
Examiner <i>Wapak Long</i>		Date Considered 2/9/01.

RJT/lvb
K:\PAT\Bayer\9\c1\1449.wpd